corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 12699

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

Lawler B.
Who Let the Docs Out?
The Motley Fool 2008 Jan 31
http://www.fool.com/investing/dividends-income/2008/01/31/who-let-the-docs-out.aspx


Full text:

GlaxoSmithKline’s diabetes drug Avandia found itself back in the news yesterday, after a U.S. senator discovered that Glaxo learned the details of a negative study before they were published.

The negative study in question is the New England Journal of Medicine Avandia safety meta-analysis published last year. It suggested that using Avandia may cause an increased incidence of certain cardiovascular adverse events. Apparently, a peer reviewer of the article sent Glaxo an unauthorized advance copy 17 days ahead of its publication. Now Sen. Charles Grassley of Iowa wants to know what Glaxo did with that information.

Before being published, a scholarly journal article goes through the peer review process, in which its authors solicit additions, corrections, and other suggested changes for the article. Reviewers often include prominent academic members of the field in question, who generally have to agree not to publicly discuss the article or its data before it gets published. Leaking data early is unethical, and it diminishes the importance of the journal.

So why the big wah-wah over a prematurely leaked journal article? Investors and analysts have been a little jittery these past weeks regarding any hint of impropriety among drugmakers. Merck and partner Schering-Plough have been embroiled in their own congressional brouhaha, accused of delaying the release of key data from a clinical study that ultimately revealed negative results about their blockbuster cholesterol drug Vytorin.

Merck and Schering have already been hit by lawsuits regarding the Vytorin data, and of course, nobody has to be reminded of the $4.85 billion settlement that Merck just agreed to pay to resolve alleged Vioxx disclosure issues. All these events have some investors imagining billions of British pounds flying out of Glaxo’s balance sheet, should Avandia prompt a similar situation.

Thankfully, Glaxo doesn’t appear to have done anything wrong with the document leak. Apparently, the company never tried to distort any data or pressure any investigators in the brief window before the article’s publication. While this leak definitely reflects poorly on the reviewer who broke a confidentiality agreement with the New England Journal of Medicine, it’s much ado about nothing for Glaxo.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend








...to influence multinational corporations effectively, the efforts of governments will have to be complemented by others, notably the many voluntary organisations that have shown they can effectively represent society’s public-health interests…
A small group known as Healthy Skepticism; formerly the Medical Lobby for Appropriate Marketing) has consistently and insistently drawn the attention of producers to promotional malpractice, calling for (and often securing) correction. These organisations [Healthy Skepticism, Médecins Sans Frontières and Health Action International] are small, but they are capable; they bear malice towards no one, and they are inscrutably honest. If industry is indeed persuaded to face up to its social responsibilities in the coming years it may well be because of these associations and others like them.
- Dukes MN. Accountability of the pharmaceutical industry. Lancet. 2002 Nov 23; 360(9346)1682-4.